The value of KRAS mutation testing with CEA for the diagnosis of pancreatic mucinous cysts
| Autor: | Abdurrahman Kadayifci, Mohammad Al-Haddad, Mustafa Atar, John M. Dewitt, David G. Forcione, Stuart Sherman, Brenna W. Casey, Carlos Fernandez-del Castillo, C. Max Schmidt, Martha B. Pitman, William R. Brugge |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Endoscopy International Open, Vol 04, Iss 04, Pp E391-E396 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2364-3722 2196-9736 |
| DOI: | 10.1055/s-0042-101755 |
| Popis: | Background and aims: Pancreatic cyst fluid (PCF) CEA has been shown to be the most accurate preoperative test for detection of cystic mucinous neoplasms (CMNs). This study aimed to assess the added value of PCF KRAS mutational analysis to CEA for diagnosis of CMNs. Patients and methods: This is a retrospective study of prospectively collected endoscopic ultrasonography (EUS) fine-needle aspiration (FNA) data. KRAS mutation was determined by direct sequencing or equivalent methods. Cysts were classified histologically (surgical cohort) or by clinical (EUS or FNA) findings (clinical cohort). Performance characteristics of KRAS, CEA and their combination for detection of a cystic mucinous neoplasm (CMN) and malignancy were calculated. Results: The study cohort consisted of 943 patients: 147 in the surgical cohort and 796 in the clinical cohort. Overall, KRAS and CEA each had high specificity (100 % and 93.2 %), but low sensitivity (48.3 % and 56.3 %) for the diagnosis of a CMN. The positivity of KRAS or CEA increased the diagnostic accuracy (80.8 %) and AUC (0.84) significantly compared to KRAS (65.3 % and 0.74) or CEA (65.8 % and 0.74) alone, but only in the clinical cohort (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|